Chen, Triatin, Luo, Snieder, Schmidt, Ditmarsch, Kastelein, Dullaart, Kuivenhoven, & Thio (2026). Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.. Cardiovascular diabetology.
Chen, Triatin, Luo, Snieder, Schmidt, Ditmarsch, et al. Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.. Cardiovascular diabetology. 2026; PMID: 42135799
Chen, Triatin, Luo, et al. Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.[J]. Cardiovascular diabetology. 2026.
@article{chen2026,
author = {Chen and Triatin and Luo and Snieder and Schmidt and Ditmarsch and Kastelein and Dullaart and Kuivenhoven and Thio},
title = {Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.},
journal = {Cardiovascular diabetology},
year = {2026},
note = {PMID: 42135799},
}
TY - JOUR AU - Chen AU - Triatin AU - Luo AU - Snieder AU - Schmidt AU - Ditmarsch AU - Kastelein AU - Dullaart AU - Kuivenhoven AU - Thio TI - Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study. T2 - Cardiovascular diabetology PY - 2026 AN - PMID:42135799 ER -
Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) is the cornerstone in the prevention of coronary artery disease (CAD) but may also increase risk of type 2 diabetes (T2D). A comprehensive examination of the genetic evidence of T2D related side-effects of all current lipid-modifying drugs, including those in development, has not yet been performed.